임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 21-06-10 09:56
논문번호 254
논문제목(영문) Effect of renin-angiotensin system inhibitors on major clinical outcomes in patients with acute myocardial infarction and prediabetes or diabetes after successful implantation of newer-generation drug-eluting stents.
국내외구분 국외 SCI여부 SCI(E)
연구책임자역할 공저자
주저자명 Kim YH, Her AY
교신저자명 Kim YH
공동저자명 Jeong MH, Kim BK, Hong SJ, Kim S, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y
게제년월일 2020-06-01
ISSN 1056-8727
Impact Factor 2.781
학술지명 JOURNAL OF DIABETES AND ITS COMPLICATIONS
서지사항 0집 / 34권 / 6호,   페이지(107574 - 107574)
요약초록문
(Abstract) 입력		 Aim: To investigate the comparative effectiveness of renin-angiotensin system inhibitor (RASI) therapy on major clinical outcomes in patients with acute myocardial infarction (AMI) and prediabetes or diabetes after successful percutaneous coronary intervention (PCI) with newer-generation drug-eluting stents (DESs).

Methods: A total of 11,962 patients with AMI were divided into six groups according to glycemic status and the presence or absence of RASI therapy: normoglycemia (n = 3,080; RASI- [n = 2,496], RASI- [n = 584]), prediabetes (n = 3,709; RASI- [n = 2,9441, RASI- [n = 765]), and diabetes (n = 5,173; RASI- [n = 4,1331, RASI- [n 1,040]). The major endpoint was major adverse cardiac events (MACEs), defined as all-cause death, recurrent myocardial infarction (re-MI), or any repeat revascularization.

Results: After adjustment, in RASI users, the cumulative incidence of re-MI of the diabetes group was significantly higher than that of the prediabetes group (aHR, 1.999; 95% CI, 1.153-3.467; p- 0.014). However, the cumulative incidences of MACEs, all-cause death, and any repeat revascularization were similar between the two groups during a 2-year follow-up period.

Conclusions: In the era of newer-generation DESs, RASI therapy did not reduce re-MI in patients with AMI and diabetes in this study. (C) 2020 Elsevier Inc. All rights reserved.
파일